Hls Therapeutics
(TSX) HLS
Hls Therapeutics Financials at a Glance
Market Cap
CA$136.04M
Revenue (TTM)
$55.76M
Net Income (TTM)
-$10.27M
EPS (TTM)
-CA$0.45
P/E Ratio
-9.62
Dividend
CA$0.00
Beta (Volatility)
0.50 (Low)
Dividend
CA$0.00
Beta (Volatility)
0.50 (Low)
Price
CA$4.35
Volume
5,160
Open
CA$4.35
Price
CA$4.35
Volume
5,160
Open
CA$4.35
Previous Close
CA$4.35
Daily Range
CA$4.34 - CA$4.41
52-Week Range
CA$4.22 - CA$5.77
Estimated Earnings Date
Aug 13, 2026
Dividend
CA$0.00
Beta (Volatility)
0.50 (Low)
Price
CA$4.35
Volume
5,160
Open
CA$4.35
Previous Close
CA$4.35
Daily Range
CA$4.34 - CA$4.41
52-Week Range
CA$4.22 - CA$5.77
Estimated Earnings Date
Aug 13, 2026
HLS News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Hls Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
85
CEO
Craig Millian, MBA
Website
www.hlstherapeutics.comHeadquarters
Etobicoke, ON M9W 6L2, CA
HLS Financials
Key Financial Metrics (TTM)
Gross Margin
62%
Operating Margin
-7%
Net Income Margin
-18%
Return on Equity
-16%
Return on Capital
-4%
Return on Assets
-8%
Earnings Yield
-10.40%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
CA$136.04M
Shares Outstanding
31.27M
Volume
5.16K
Avg. Volume
6.54K
Financials (TTM)
Gross Profit
$24.01M
Operating Income
-$4.18M
EBITDA
$18.02M
Operating Cash Flow
$16.02M
Capital Expenditure
-$208.59K
Free Cash Flow
$15.81M
Cash & ST Invst.
$11.70M
Total Debt
$49.73M
Hls Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$12.65M
+0.2%
Gross Profit
$4.57M
-55.3%
Gross Margin
36.12%
N/A
Market Cap
CA$136.04M
N/A
Market Cap/Employee
CA$1.48M
N/A
Employees
92
N/A
Net Income
-$2.26M
+49.1%
EBITDA
$3.27M
+11.9%
Quarterly Fundamentals
Total Cash
$12.33M
-30.4%
Total Debt
$43.96M
-31.0%
Accounts Receivable
$8.14M
+16.6%
Inventory
$7.37M
-1.5%
Long Term Debt
$39.24M
-32.4%
Short Term Debt
$4.72M
-17.1%
Return on Assets
-7.82%
N/A
Return on Invested Capital
-3.99%
N/A
Free Cash Flow
$6.26M
+77.8%
Operating Cash Flow
$6.26M
+76.8%